Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) Meeting Abstract
| Authors: | Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Pardo, P. G.; Jhaveri, K.; Delaney, R. J.; Valdez, T.; Wang, H.; Verret, W.; Tolaney, S. M. |
| Abstract Title: | Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1386 |
| Language: | English |
| ACCESSION: | WOS:000866211602422 |
| DOI: | 10.1016/j.annonc.2022.08.012 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA76 -- Source: Wos |
